Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

Basal Health vs BeyondMD

Basal Health
Graded #494

Lower grade

vs+19.099999999999994
BeyondMD
Graded #176

Higher grade

The verdict

BeyondMD takes it — 66.8/100 to 47.7/100.

BeyondMD grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Telehealth clinic offering competitively priced compounded semaglutide and tirzepatide.

We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.

Factor by factor

The same six graded dimensions, side by side. See the methodology.

Cost valueBeyondMD +31
45
76
Dose & formulationBeyondMD +24
40
64
Clinical oversightBeyondMD +26
48
74
Labs & monitoringBeyondMD +3
50
53
FulfillmentBeyondMD +7
58
65
Contract termsEven
55
55
Basal Health · left barBeyondMD · right bar

The numbers

MetricBasal HealthBeyondMD
WeighScore47.7/10066.8/100
GradeCC
Scorecard rank#494#176
SemaglutideNot disclosed$139/mo (starting dose, compounded)
TirzepatideNot disclosed$209/mo (starting dose, compounded)
CoverageAll 50 statesCoverage not published
Brand-name accessCompounded onlyCompounded only
Oral / sublingualInjection onlyInjection only
Basal Health

Graded #494 · C

Strengths

  • Stated nationwide coverage (50 states + DC)
  • Metabolic-framework positioning rather than single-product
  • Clinician-supervised dosing rather than a fixed protocol
  • Adaptive monitoring approach

Where it loses points

  • No pricing shown publicly — you must complete intake to see cost
  • Compounding pharmacy partner not named
  • GLP-1 molecules not specified (semaglutide vs tirzepatide vs oral)
  • No LegitScript badge visible on the homepage
  • No FDA compounded-medication disclaimer on the pages reviewed
BeyondMD

Graded #176 · C

Strengths

  • Aggressively low monthly pricing
  • Both semaglutide and tirzepatide available
  • Compounded GLP-1 access

Where it loses points

  • Limited public information on program details

Also worth a look

Neither is our top-graded pick — CoreAge Rx leads the scorecard

Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.

Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.

← Back to the scorecard